BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2016;196:225-33. [DOI: 10.1016/j.jad.2016.02.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Zheng G, Fu T, Hong J, Li F, Yao X, Xue W, Zhu F. The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations. Phys Chem Chem Phys 2020;22:5132-44. [PMID: 32073004 DOI: 10.1039/c9cp05764a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Zareifopoulos N, Papatheodoropoulos C. Effects of 5-HT-7 receptor ligands on memory and cognition. Neurobiol Learn Mem 2016;136:204-9. [PMID: 27780766 DOI: 10.1016/j.nlm.2016.10.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
3 Micov AM, Tomić MA, Todorović MB, Vuković MJ, Pecikoza UB, Jasnic NI, Djordjevic JD, Stepanović-Petrović RM. Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. Prog Neuropsychopharmacol Biol Psychiatry 2020;103:109975. [PMID: 32464241 DOI: 10.1016/j.pnpbp.2020.109975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Wang HR, Bahk WM, Seo JS, Woo YS, Park YM, Jeong JH, Kim W, Shim SH, Lee JG, Jon DI, Min KJ. Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines. Clin Psychopharmacol Neurosci 2017;15:199-209. [PMID: 28783928 DOI: 10.9758/cpn.2017.15.3.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. J Affect Disord 2018;228:1-12. [PMID: 29197738 DOI: 10.1016/j.jad.2017.11.056] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
7 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O'Day K. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. J Affect Disord 2021;285:112-9. [PMID: 33640861 DOI: 10.1016/j.jad.2021.02.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019;15:1249-58. [PMID: 31190831 DOI: 10.2147/NDT.S199746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
10 Cooper DB, Bowles AO, Kennedy JE, Curtiss G, French LM, Tate DF, Vanderploeg RD. Cognitive Rehabilitation for Military Service Members With Mild Traumatic Brain Injury: A Randomized Clinical Trial. Journal of Head Trauma Rehabilitation 2017;32:E1-E15. [DOI: 10.1097/htr.0000000000000254] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
11 Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci 2020;74:140-8. [PMID: 31725942 DOI: 10.1111/pcn.12956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. Asian Journal of Psychiatry 2017;26:115-22. [DOI: 10.1016/j.ajp.2017.01.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
13 Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Christensen MC, Munro V. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Current Medical Research and Opinion 2018;34:593-600. [DOI: 10.1080/03007995.2017.1416952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Potměšil P. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? Ther Adv Psychopharmacol 2019;9:2045125319855206. [PMID: 31312426 DOI: 10.1177/2045125319855206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Vo P, Wen S, Martel M, Mitsikostas D, Reuter U, Klatt J. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia 2019;39:608-16. [DOI: 10.1177/0333102418801579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
17 Gerbasi ME, Meltzer-Brody S, Acaster S, Fridman M, Bonthapally V, Hodgkins P, Kanes SJ, Eldar-Lissai A. Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making. J Womens Health (Larchmt) 2021;30:385-92. [PMID: 33181049 DOI: 10.1089/jwh.2020.8483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. Int Clin Psychopharmacol 2020;35:305-12. [PMID: 32784346 DOI: 10.1097/YIC.0000000000000326] [Reference Citation Analysis]
19 Nakatani Y, Amano T. Contributions of S- and R-citalopram to the citalopram-induced modulation of the function of Nav1.5 voltage-gated sodium channels. Eur J Pharmacol 2021;908:174316. [PMID: 34280395 DOI: 10.1016/j.ejphar.2021.174316] [Reference Citation Analysis]
20 Citrome L, Dibernardo A, Singh J. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2020;271:228-38. [DOI: 10.1016/j.jad.2020.03.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, Perna G, Iasevoli F, Martinotti G, Di Giannantonio M. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. Braz J Psychiatry 2020;42:317-21. [PMID: 32159712 DOI: 10.1590/1516-4446-2019-0690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]